Speech by Chancellor Olaf Scholz at the groundbreaking ceremony for the new production site of Eli Lilly and Company on April 8, 2024, in Alzey:

Germany Olaf Scholz · Member of the Bundestag

9 April 2024 · Groundbreaking ceremony for the new production site of Eli Lilly and Company · Alzey, Germany

Context
Scholz spoke at the groundbreaking ceremony for Eli Lilly's new €2.3 billion pharmaceutical production facility in Alzey, Germany, on April 8, 2024.
Main themes
Pharmaceutical investment in Germany, Eli Lilly groundbreaking ceremony, job creation, Germany as industrial location, Rhineland-Palatinate biotech cluster, local governance and permitting speed, citizen involvement in urban planning, pharmaceutical innovation, Germany's reunification-era economic milestones
Duration
~12 min
43rd percentile
Words
1,473
43rd percentile
Sentences
86
56th percentile
Readability
51
67th percentile
Grade
10.2
22nd percentile
Syntax
2.89
32nd percentile
Vocabulary
2.17
42nd percentile

Translated from German

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Economic 38%35%
  • Ceremonial 29%27%
  • Social 22%20%
  • Institutional 9%8%
  • Geopolitical 1%1%
  • Technological 0%0%
  • Environmental 0%0%
  • Not in focus 9%

86 sentences in 23 paragraphs

Dear Mr. Ricks, dear Dave,

dear Madam Minister-President, dear Malu,

esteemed members of parliament, ministers,

Mr. Consul General Scharpf,

Mr. District Administrator,

Mr. Mayor,

dear employees of Lilly,

ladies and gentlemen!

Even this long address shows: Today is a special day for Alzey and for the entire region – a particularly good day. We have just heard: Lilly is investing 2.3 billion euros here in the establishment of a new, state-of-the-art production facility for pharmaceuticals. 1,000 good jobs are to be created here. We are talking about one, if not the largest single investment in the pharmaceutical location Germany since reunification.

I have been informed that some of the long-standing residents of Alzey are reminded of an event from the 1960s and 1970s. Back then, there was already a breakthrough in and out of Alzey. The entrepreneur Karl-Heinz Kipp opened the first large self-service department store on greenfield land right here, in the East industrial area. Customers literally rushed through the doors. It was a small economic miracle made in Alzey.

Dear Mayor Jung, you have told my colleagues what you are currently hearing at many anniversary celebrations and milestone birthdays, especially from the older generation, namely that something similar is now getting underway, that there can be a new breakthrough here in Alzey just like back then. I find that remarkable and also touching. Too often, people mourn a good old time instead of embracing a good new time. The foundations for this good new time are being laid together today.

The success story of Alzey has many mothers and fathers. I would like to extend my heartfelt thanks to some of them today. First and foremost is, of course, the company itself, Lilly, which clearly commits to Germany as a strong, leading pharmaceutical and industrial location with this investment. We are pleased, because Lilly brings great experience. 101 years ago, your company brought the first industrially produced insulin to market. One of the researchers who achieved this was the chemist George Clowes, trained in Germany, by the way. Lilly is still committed to the fight against diabetes today. Lilly's medicines save lives, alleviate diseases, including in neurology, oncology, immunology, and many other areas.

The success story of Alzey also includes the state of Rhineland-Palatinate. Dear Malu, esteemed Minister Schmitt, the state has really done everything right in building the biotech and life sciences cluster. Strong basic research, practical research institutions, targeted promotion of innovations, an active settlement policy – all of this is now paying off.

It was less than a year ago that we were together at Boehringer in Ingelheim and laid the foundation stone for the new "Chemical Innovation Plant." Since then, you have opened the German headquarters of Novo Nordisk in Mainz. BioNTech is building a new building for its cancer research there; so is the Helmholtz Institute together with the German Cancer Research Center and the University of Mainz. Just at the beginning of the year, a new institute started its work at the university, aiming to advance life sciences through computer-based methods, and as I hear, there are also promising developments a bit further up the Rhine in Ludwigshafen, at AbbVie. The breakthrough that is currently taking place here is already phenomenal.

One thing is essential for such settlements, and that is strong local partners who drive progress and clear obstacles. Because most regulations are the same everywhere in Germany. The difference is made when decisions are made locally to set things up as quickly and straightforwardly as possible. That this is possible and how it is done has been proven by all those who bear responsibility here at the municipal level, foremost the development company Alzey. It has only been eleven months since Lilly and the responsible parties from Alzey first made contact. After just six months, the announcement of this billion-euro investment followed, and now, just five months later, the groundbreaking ceremony. That is record-breaking! For the Alzey pace that you are setting, I would like to say thank you, Mr. District Administrator, and to you, Mr. Mayor, on behalf of your employees on the ground: Thank you very much!

One thing is important in this regard – and Alzey can serve as a model in this respect – namely, how you have involved the citizens. Because, of course, such a large project changes the city and the entire region. Until now, many residents of Alzey commute to work in Mainz or the other major cities in the Rhine-Main area. In the future, there will also be a reverse trend. Some of the new employees of Lilly will certainly want to move here, as beautiful as it is here in Rheinhessen. This means that the city needs enough housing, as well as school and daycare places. It is good when all of this is considered and planned from the very beginning, as is the case here in Alzey. It is also good that Lilly itself sought to engage with the citizens from the very start. Of course, the cohesion and the proverbial openness of the people in this area help, which the Rhineland-Palatinate native Carl Zuckmayer aptly referred to as the "press of Europe." This was not only related to the wine produced here but especially to the different peoples and tribes that have passed through here since Roman times and often stayed.

I would like to add one more thing. That is why I have come here today. Whatever we as the federal government can do to further strengthen the pharmaceutical location Germany, we will do. I remember our phone call, dear Dave Ricks, and how many discussions you have had with the Minister of Economics, the Minister of Health, and the Minister of Science to set the course for this investment.

Similar investments are also taking place beyond the borders of Rhineland-Palatinate. Daiichi-Sankyo is investing over one billion euros in Bavaria, Roche over one billion euros in Bavaria and Baden-Württemberg, Merck up to 1.5 billion euros in Hesse by 2025, to name just a few of the larger ones. This has to do with a world-class network of machine and plant builders, suppliers, and research institutions, and of course with the excellently trained employees we have in Germany.

However, the fact that these investment decisions are coming in rapid succession right now is also due to how we as the federal government have changed things. In no other large country in Europe are the expenditures for research and development higher than in Germany. For this reason, Germany ranks second in patent applications in the health sector, behind the USA. Just recently, we improved the tax depreciation options for research expenses once again. With a new future fund of ten billion euros until 2030, we are supporting start-ups, many of which are also in the pharmaceutical sector and in the life sciences. We have mitigated supply shortages for important medicines through targeted price adjustments. With the pharmaceutical strategy and the Medical Research Act, we are now setting incentives for more research and production in Germany and Europe. With the Medical Research Act, we will also simplify clinical trials and reduce bureaucracy. This is a central milestone of our pharmaceutical strategy, and I thank Minister Lauterbach for advancing this so decisively.

We are also working on a pharmaceutical package in the European Union that will accelerate approval processes across Europe. In doing so, we ensure that research and innovation remain worthwhile in the future and that copyrights are protected. You just explained to me in our conversation how significant this is and how Germany is the one country in the world that consistently protects copyrights, "intellectual property," and insists in many international conferences that this is a foundation for research and innovation. It is not easy when you are sometimes the only one who raises their voice loudly, but so far it has been quite successful.

Progress is also being made with health data. Just a few days ago, a new law came into effect that facilitates access to health data for researching pharmaceutical companies. Together with the European Health Data Space, this strengthens our research location in international competition. All of these are building blocks that make success stories like this one in Alzey possible. As a federal government, we will remain on the ball.

On the way here from the airport in Wiesbaden, you pass many melodious place names. These are places that every wine lover knows: Saulheim, Udenheim, Armsheim, Alzey, of course. That will not change. But one thing is different since today. In the future, Alzey and the region will no longer only be known for their good wine but also as a strong center of the pharmaceutical industry in Germany, thanks to Lilly and to all those who are writing this success story.

Thank you very much for that!